Medical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents

References

• Vogel H. Weapons of mass destruction, WMD. Eur J Radiol. 2007;63:205–213.
   PubMed Web of Science ®Google Scholar
• Prockop LD. Weapons of mass destruction: overview of the CBRNEs (Chemical, Biological, Radiological, Nuclear, and Explosives). J Neurol Sci. 2006;249:50–54.
   PubMed Web of Science ®Google Scholar
• Salem H. Issues in chemical and biological terrorism. Int J Toxicol. 2003;22:465–471.
   PubMed Web of Science ®Google Scholar
• Maher C, Hu-Primmer J, MacGill T, et al. Meeting the challenges of medical countermeasure development. Microb Biotechnol. 2012;5:588–593.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA’s Medical Countermeasures Initiative Year‐1 Status Report — September 2011. 2011. [cited 2016 Jun 17]. Available from: http://www.fda.gov/downloads/EmergencyPreparedness/MedicalCountermeasures/UCM270750.pdf.
   Google Scholar
• Thiermann H, Worek F, Kehe K. Limitations and challenges in treatment of acute chemical warfare agent poisoning. Chem Biol Interact. 2013;206:435–443.
   PubMed Web of Science ®Google Scholar
• Timbie JW, Ringel JS, Fox DS, et al. Systematic review of strategies to manage and allocate scarce resources during mass casualty events. Ann Emerg Med. 2013;61:677–689 e101.
   PubMed Web of Science ®Google Scholar
• Gronvall GK, Trent D, Borio L, et al. The FDA Animal Efficacy Rule and biodefense. Nat Biotechnol. 2007;25:1084–1087.
   PubMed Web of Science ®Google Scholar
• Singh VK, Newman VL, Berg AN, et al. Animal models for acute radiation syndrome drug discovery. Expert Opin Drug Discov. 2015;10:497–517.
   PubMed Web of Science ®Google Scholar
• Aebersold P. FDA experience with medical countermeasures under the Animal Rule. Adv Prev Med. 2012;2012:507571.
   PubMedGoogle Scholar
• Singh VK, Newman VL, Romaine PL, et al. Use of biomarkers for assessing radiation injury and efficacy of countermeasures. Expert Rev Mol Diagn. 2016;16:65–81.
   PubMed Web of Science ®Google Scholar
• Russell PK. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis. 2007;45(Suppl 1):S68–S72.
   PubMed Web of Science ®Google Scholar
• Need JT, Mothershead JL. Strategic National Stockpile program: implications for military medicine. Mil Med. 2006;171:698–702.
   PubMed Web of Science ®Google Scholar
• Esbitt D. The Strategic National Stockpile: roles and responsibilities of health care professionals for receiving the stockpile assets. Disaster Manag Response. 2003;1:68–70.
   PubMedGoogle Scholar
• Gronvall G. Biodefense countermeasures: the impact of Title IV of the US Pandemic and All-Hazards Preparedness Act. Emerg Health Threats J. 2008;1:e3.
   PubMedGoogle Scholar
• Wright LK, Lee RB, Vincelli NM, et al. Comparison of the lethal effects of chemical warfare nerve agents across multiple ages. Toxicol Lett. 2016;241:167–174.
   PubMed Web of Science ®Google Scholar
• Newmark J. Nerve agents. Neurologist. 2007;13:20–32.
   PubMed Web of Science ®Google Scholar
• Bailey AM, Baker SN, Baum RA, et al. Being prepared: emergency treatment following a nerve agent release. Adv Emerg Nurs J. 2014;36:22–33. quiz 34-5
   PubMedGoogle Scholar
• Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38:152–155.
   PubMed Web of Science ®Google Scholar
• Nachon F, Brazzolotto X, Trovaslet M, et al. Progress in the development of enzyme-based nerve agent bioscavengers. Chem Biol Interact. 2013;206:536–544.
   PubMed Web of Science ®Google Scholar
• Leadbeater L, Inns RH, Rylands JM. Treatment of poisoning by soman. Fundam Appl Toxicol. 1985;5:S225–S231.
   PubMedGoogle Scholar
• Von Bredow JD, Adams NL, Groff WA, et al. Effectiveness of oral pyridostigmine pretreatment and cholinolytic-oxime therapy against soman intoxication in nonhuman primates. Fundam Appl Toxicol. 1991;17:761–770.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. FDA approves pyridostigmine bromide as pretreatment against nerve gas. 2003. [cited 2016 Jan 12]. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130342.htm.
   Google Scholar
• Lawson-Smith P, Jansen EC, Hyldegaard O. Cyanide intoxication as part of smoke inhalation -A review on diagnosis and treatment from the emergency perspective. Scand J Trauma Resusc Emerg Med. 2011;19:14.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves drug to treat cyanide poisoning. 2006. [cited 2016 Jan 13]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108807.htm.
   Google Scholar
• Borron SW, Stonerook M, Reid F. Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs. Clin Toxicol (Phila). 2006;44(Suppl 1):5–15.
   PubMed Web of Science ®Google Scholar
• Jenner J, Graham SJ. Treatment of sulphur mustard skin injury. Chem Biol Interact. 2013;206:491–495.
   PubMed Web of Science ®Google Scholar
• Gosden C, Gardener D. Weapons of mass destruction–threats and responses. BMJ. 2005;331:397–400.
   PubMed Web of Science ®Google Scholar
• Pohanka M. Antioxidants countermeasures against sulfur mustard. Mini Rev Med Chem. 2012;12:742–748.
   PubMed Web of Science ®Google Scholar
• Zapanta PE, Ghorab S. Age of bioterrorism: are you prepared? Review of bioweapons and their clinical presentation for otolaryngologists. Otolaryngol Head Neck Surg. 2014;151:208–214.
   PubMed Web of Science ®Google Scholar
• Gluodenis T, Harrison S. Homeland security and bioterrorism applications: detection of bioweapon pathogens by microfluidic-based electrophoretic DNA analysis. MLO Med Lab Obs. 2004;36:34–38.
   PubMedGoogle Scholar
• Pettineo C, Aitchison R, Leikin SM, et al. Biological and chemical weapons of mass destruction: updated clinical therapeutic countermeasures since 2003. Am J Ther. 2009;16:35–43.
   PubMed Web of Science ®Google Scholar
• Espelund M, Klaveness D. Botulism outbreaks in natural environments – An update. Front Microbiol. 2014;5:287.
   PubMed Web of Science ®Google Scholar
• Horowitz BZ. Type E botulism. Clin Toxicol (Phila). 2010;48:880–895.
   PubMed Web of Science ®Google Scholar
• Chudzicka A. Intoxication of botulinum toxin. Pol Merkur Lekarski. 2015;39:153–156.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep. 2010;59:299.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. FDA approves first Botulism antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. 2013. [cited 2016 Jan 14]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm.
   Google Scholar
• World Health Organization. Anthrax in humans and animals. 4th ed. Geneva: World Health Organization; 2008.
   Google Scholar
• Duncan EJ, Kournikakis B, Ho J, et al. Pulmonary deposition of aerosolized Bacillus atrophaeus in a Swine model due to exposure from a simulated anthrax letter incident. Inhal Toxicol. 2009;21:141–152.
   PubMed Web of Science ®Google Scholar
• Schneemann A, Manchester M. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol. 2009;4:35–43.
   PubMed Web of Science ®Google Scholar
• Zakowska D, Bartoszcze M, Niemcewicz M, et al. New aspects of the infection mechanisms of Bacillus anthracis. Ann Agric Environ Med. 2012;19:613–618.
   PubMed Web of Science ®Google Scholar
• Twenhafel NA. Pathology of inhalational anthrax animal models. Vet Pathol. 2010;47:819–830.
   PubMed Web of Science ®Google Scholar
• Williamson ED, Dyson EH. Anthrax prophylaxis: recent advances and future directions. Front Microbiol. 2015;6:1009.
   PubMed Web of Science ®Google Scholar
• Cangene Corporation/Emergent BioSolution. Highlights of prescribing information - Anthrasil. 2015. [cited 2016 Jan 17]. Available from: http://emergentbiosolutions.com/sites/default/files/AIG_PI_2015.pdf.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves treatment for inhalation anthrax. 2015. [cited 2016 Jan 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm.
   Google Scholar
• Mazumdar S. Raxibacumab. mAbs. 2009;1:531–538.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves Raxibacumab to treat inhalational anthrax. 2012. [cited 2016 Jan 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm.
   Google Scholar
• Tsai CW, Morris S. Approval of Raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration “Animal Rule”. Front Microbiol. 2015;6:1320.
   PubMed Web of Science ®Google Scholar
• Corey A, Migone TS, Bolmer S, et al. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/Raxibacumab-treated New Zealand white rabbits. Toxins (Basel). 2013;5:120–138.
   PubMed Web of Science ®Google Scholar
• Migone TS, Bolmer S, Zhong J, et al. Added benefit of Raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother. 2015;59:1145–1151.
   PubMed Web of Science ®Google Scholar
• GSK group of companies. Highlights of prescribing information - Raxibacumab. 2015. [cited 2016 Jan 16]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Raxibacumab/pdf/RAXIBACUMAB-PI-PIL.PDF
   Google Scholar
• Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis. 2005;41:12–20.
   PubMed Web of Science ®Google Scholar
• Meaney-Delman D, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women. Obstet Gynecol. 2013;122:885–900.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Onodera Y, Uchida Y, et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother. 1997;41:2362–2366.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc. Highlights of prescribing information - Levaquin for plague and anthrax. 2013. [cited 2016 Jan 17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020634s065,020635s071,021721s032lbl.pdf.
   Google Scholar
• U.S. Food and Drug Administration. Levaquin (levofloxacin) information for inhalational anthrax. 2016. [cited 2016 Jan 18]. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133678.htm.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves vaccine for use after known or suspected anthrax exposure. 2015. [cited 2016 Jan 19]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474027.htm.
   Google Scholar
• Emergent BioSolutions. BioThrax (anthrax vaccine adsorbed). 2015. [cited 2016 Jan 20]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/UCM074923.pdf.
   Google Scholar
• U.S. Food and Drug Administration. Cipro (ciprofloxacin hydrochloride) for inhalation anthrax. 2015. [cited 2016 Jan 29]. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130709.htm.
   Google Scholar
• Kelly DJ, Chulay JD, Mikesell P, et al. Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis. 1992;166:1184–1187.
   PubMed Web of Science ®Google Scholar
• Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239–1243.
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceuticals Corporation. Medication guide - Ciprofloxacin hydrochloride. 2015. [cited 2016 Jan 29]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/ucm246794.pdf.
   Google Scholar
• Bayer Pharmaceuticals Corporation. CIPRO. 2005. [cited 2016 Jun 19]. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4152b1_03_05_02_Cipro%20label%20injection%20FDA%201-7-05.pdf.
   Google Scholar
• Ligon BL. Plague: a review of its history and potential as a biological weapon. Semin Pediatr Infect Dis. 2006;17:161–170.
   PubMedGoogle Scholar
• Steward J, Lever MS, Russell P, et al. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. Int J Antimicrob Agents. 2004;24:609–612.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves additional antibacterial treatment for plague. 2015. [cited 2016 Jan 15]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm446283.htm.
   Google Scholar
• U.S. Food and Drug Administration. Ciprofloxacin - Supplemental NDA approved to add indication for treatment and prophylaxis of plague due to Yersinia pestis in adults and pediatric patients. 2015. [cited 2016 Jan 29]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/019537Orig1s083,019847Orig1s055,019857Orig1s063,020780Orig1s041ltr.pdf.
   Google Scholar
• Carlsbad Technology Inc. Ciprofloxacin. 2016. [cited 2016 Jun 19]. Available from: https://www.drugs.com/pro/ciprofloxacin.html.
   Google Scholar
• Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med. 2001;21:593–605.
   PubMed Web of Science ®Google Scholar
• Ulu-Kilic A, Doganay M. An overview: tularemia and travel medicine. Travel Med Infect Dis. 2014;12:609–616.
   PubMed Web of Science ®Google Scholar
• El-Mahallawy HS, Lu G, Kelly P, et al. Q fever in China: a systematic review, 1989–2013. Epidemiol Infect. 2015;143:673–681.
   PubMed Web of Science ®Google Scholar
• Weiss RA, Esparza J. The prevention and eradication of smallpox: a commentary on Sloane (1755) ‘An account of inoculation’. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140378.
   PubMed Web of Science ®Google Scholar
• Jones T. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Curr Opin Mol Ther. 2008;10:407–417.
   PubMedGoogle Scholar
• Pita R, Romero A. Toxins as weapons: a historical review. Forensic Sci Rev. 2014;26:85–96.
   PubMedGoogle Scholar
• Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000;13:16–34.
   PubMed Web of Science ®Google Scholar
• Wesołowski A, Płusa T. [Saxitoxins and tetrodotokxins as a new biological weapon]. Pol Merkur Lekarski. 2015;39:173–175.
   PubMedGoogle Scholar
• Albuquerque EX, Pereira EF, Aracava Y, et al. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci USA. 2006;103:13220–13225.
   PubMed Web of Science ®Google Scholar
• Hilmas CJ, Poole MJ, Finneran K, et al. Galantamine is a novel post-exposure therapeutic against lethal VX challenge. Toxicol Appl Pharmacol. 2009;240:166–173.
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. Galantamine–a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8:159–176.
   PubMedGoogle Scholar
• Albuquerque EX, Adler M, Pereira EFR. Method of treating organophosphorous poisoning. US9132135B2. 2015.
   Google Scholar
• Grunwald J, Raveh L, Doctor BP, et al. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 1994;54:991–997.
   PubMed Web of Science ®Google Scholar
• Shaikh S, Verma A, Siddiqui S, et al. Current acetylcholinesterase-inhibitors: a neuroinformatics perspective. CNS Neurol Disord Drug Targets. 2014;13:391–401.
   PubMed Web of Science ®Google Scholar
• Marks JD, Amersdorfer P, Geren I, et al. Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins. US7999079B2. 2011.
   Google Scholar
• Parikh SM. Methods and compositions for the treatment and diagnosis of systemic anthrax infection. US8685393 B2. 2014.
   Google Scholar
• Chen Z, Purcell RH, Schneerson R, et al. Monoclonal antibodies that react with the capsule of Bacillus anthracis. US8501182 B2. 2013.
   Google Scholar
• Casey LS. Methods of preventing or treating anthrax using anti-anthrax antibodies. US8617548 B2. 2013.
   Google Scholar
• Lien E, Goguen JD. Modified pathogens for use as vaccines. US9138468 B2. 2015.
   Google Scholar
• Lowell GH, Burt DS, Jones DH, et al. Compositions and methods for activating innate and allergic immunity. US8709447 B2. 2014.
   Google Scholar
• Ann J, Samant M, Rheaume C, et al. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine. 2014;32:5730–5739.
   PubMed Web of Science ®Google Scholar
• Yusibov V, Mett V, Musiychuk K. Yersinia pestis antigens, vaccine compositions, and related methods. US8945580 B2. 2015.
   Google Scholar
• Mizel SB, Honko AN. Use of flagellin in the immunotherapy of Yersinia pestis. CA2589553 C. 2014.
   Google Scholar
• Baker JR, Makidon PE, Mank NJ, et al. Multivalent nanoemulsion vaccines. US8877208 B2. 2014.
   Google Scholar
• Matheny J, Mair M, Smith B. Cost/success projections for US biodefense countermeasure development. Nat Biotechnol. 2008;26:981–983.
   PubMed Web of Science ®Google Scholar
• Cohen J. Biodefense: 10 years after reinventing Project BioShield. Science. 2011;333:1216–1218.
   PubMed Web of Science ®Google Scholar
• Singh V, Gupta D, Arora R. NF-κB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures. Discoveries. 2015;3:e35.
   Google Scholar
• Singh VK, Romaine PL, Seed TM. Medical countermeasures for radiation exposure and related injuries: characterization of medicines, FDA-approval status and inclusion into the Strategic National Stockpile. Health Phys. 2015;108:607–630.
   PubMed Web of Science ®Google Scholar
• Singh VK, Newman VL, Romaine PL, et al. Radiation countermeasure agents: an update (2011–2014). Expert Opin Ther Pat. 2014;24:1229–1255.
   PubMed Web of Science ®Google Scholar
• Kels CG. Dispensing medical countermeasures: emergency use authorities and liability protections. Health Secur. 2015;13:139–151.
   PubMed Web of Science ®Google Scholar
• Nightingale SL, Prasher JM, Simonson S. Emergency use authorization (EUA) to enable use of needed products in civilian and military emergencies, United States. Emerging Infect Dis. 2007;13:1046–1055.
   PubMed Web of Science ®Google Scholar